|
|
Article: Barr Confirms Patent Challenge of Ambien CR(R).
- Article from:
- PR Newswire
- Article date:
- April 6, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WOODCLIFF LAKE, N.J., April 6 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a patent challenge for Sanofi-Aventis U.S. LLC's Ambien CR(R) (Zolpidem Tartrate Extended-Release Tablets), 6.25mg & 12.5mg.
Barr filed its Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for a generic Ambien CR product with the U.S. Food & Drug Administration (FDA) in December 2006, and received notification of the application's acceptance for filing in February 2007. Following receipt of the notice from the FDA, Barr notified Sanofi-Aventis, the New Drug Application (NDA) ...